CN102225903A - 脒基胍基取代芳杂环类化合物的合成方法及其用途 - Google Patents
脒基胍基取代芳杂环类化合物的合成方法及其用途 Download PDFInfo
- Publication number
- CN102225903A CN102225903A CN2011101005174A CN201110100517A CN102225903A CN 102225903 A CN102225903 A CN 102225903A CN 2011101005174 A CN2011101005174 A CN 2011101005174A CN 201110100517 A CN201110100517 A CN 201110100517A CN 102225903 A CN102225903 A CN 102225903A
- Authority
- CN
- China
- Prior art keywords
- ring
- cor
- represent
- fragrant
- aromatic ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 title claims abstract description 17
- 125000006615 aromatic heterocyclic group Chemical group 0.000 title abstract 5
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- 125000003118 aryl group Chemical group 0.000 claims abstract description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 13
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 13
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 13
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- 239000005864 Sulphur Substances 0.000 claims description 6
- -1 vitriol Chemical compound 0.000 claims description 6
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 23
- 206010033645 Pancreatitis Diseases 0.000 abstract description 16
- 206010033647 Pancreatitis acute Diseases 0.000 abstract description 13
- 201000003229 acute pancreatitis Diseases 0.000 abstract description 13
- 230000001154 acute effect Effects 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract 1
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 9
- 229950002475 mesilate Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002753 trypsin inhibitor Substances 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- BFMOHRNTIFROGD-UHFFFAOYSA-N methyl 6-hydroxynaphthalene-2-carboximidate Chemical compound OC=1C=C2C=CC(=CC2=CC=1)C(OC)=N BFMOHRNTIFROGD-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229910021536 Zeolite Inorganic materials 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004923 pancreatic tissue Anatomy 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000010457 zeolite Substances 0.000 description 3
- HWTGNSKUIIUDOU-PEBGCTIMSA-N (5r,6r,7s,8r)-5-acetamido-6,7,8,9-tetrahydroxy-2-oxononanoic acid Chemical compound OC(=O)C(=O)CC[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO HWTGNSKUIIUDOU-PEBGCTIMSA-N 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 description 2
- UCVRTKSDMCHQNW-UHFFFAOYSA-N 4-[(4-nitrophenyl)methylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NCC1=CC=C([N+]([O-])=O)C=C1 UCVRTKSDMCHQNW-UHFFFAOYSA-N 0.000 description 2
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NAMGRNXMZHEICS-UHFFFAOYSA-N (6-carbamimidoylnaphthalen-2-yl) 4-(4,5-dihydro-1h-imidazol-2-ylamino)benzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC2=CC(C(=N)N)=CC=C2C=C1OC(=O)C(C=C1)=CC=C1NC1=NCCN1 NAMGRNXMZHEICS-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RSYYQCDERUOEFI-UHFFFAOYSA-N 2-benzamido-5-(diaminomethylideneazaniumyl)pentanoate Chemical compound NC(N)=NCCCC(C(O)=O)NC(=O)C1=CC=CC=C1 RSYYQCDERUOEFI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 210000004695 acinic cell Anatomy 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 1
- 229960000772 camostat Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950001371 sepimostat Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
浓度(μg/ml) | 抑制率(%) |
0.061 | 12.45 |
0.122 | 21.69 |
0.245 | 38.15 |
0.489 | 69.08 |
0.977 | 94.78 |
1.953 | 97.99 |
3.906 | 98.8 |
7.813 | 99.6 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110100517.4A CN102225903B (zh) | 2011-04-21 | 2011-04-21 | 脒基胍基取代芳杂环类化合物的合成方法及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110100517.4A CN102225903B (zh) | 2011-04-21 | 2011-04-21 | 脒基胍基取代芳杂环类化合物的合成方法及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102225903A true CN102225903A (zh) | 2011-10-26 |
CN102225903B CN102225903B (zh) | 2014-11-26 |
Family
ID=44806914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110100517.4A Expired - Fee Related CN102225903B (zh) | 2011-04-21 | 2011-04-21 | 脒基胍基取代芳杂环类化合物的合成方法及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102225903B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2504526A1 (fr) * | 1981-04-28 | 1982-10-29 | Torii & Co Ltd | Derives de l'amidine, leur procede de preparation et agents anti-complement en contenant |
US4634783A (en) * | 1983-01-28 | 1987-01-06 | Torii & Co. Ltd. | Novel amidine compound |
EP0588655A1 (en) * | 1992-09-18 | 1994-03-23 | Ono Pharmaceutical Co., Ltd. | Amidinophenol derivatives |
WO1994027958A1 (de) * | 1993-05-20 | 1994-12-08 | Boehringer Mannheim Gmbh | 4-amidinophenylsulfonamide zur behandlung von thromboembolischen erkrankungen |
CN1110679A (zh) * | 1993-12-03 | 1995-10-25 | 小野药品工业株式会社 | 脒基酚衍生物 |
JPH0820532A (ja) * | 1994-07-05 | 1996-01-23 | Dai Ichi Seiyaku Co Ltd | 抗膵炎剤 |
EP0703216A1 (en) * | 1994-09-20 | 1996-03-27 | Ono Pharmaceutical Co., Ltd. | Amidinophenol derivatives as protease inhibitors |
-
2011
- 2011-04-21 CN CN201110100517.4A patent/CN102225903B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2504526A1 (fr) * | 1981-04-28 | 1982-10-29 | Torii & Co Ltd | Derives de l'amidine, leur procede de preparation et agents anti-complement en contenant |
US4634783A (en) * | 1983-01-28 | 1987-01-06 | Torii & Co. Ltd. | Novel amidine compound |
EP0588655A1 (en) * | 1992-09-18 | 1994-03-23 | Ono Pharmaceutical Co., Ltd. | Amidinophenol derivatives |
WO1994027958A1 (de) * | 1993-05-20 | 1994-12-08 | Boehringer Mannheim Gmbh | 4-amidinophenylsulfonamide zur behandlung von thromboembolischen erkrankungen |
CN1110679A (zh) * | 1993-12-03 | 1995-10-25 | 小野药品工业株式会社 | 脒基酚衍生物 |
JPH0820532A (ja) * | 1994-07-05 | 1996-01-23 | Dai Ichi Seiyaku Co Ltd | 抗膵炎剤 |
EP0703216A1 (en) * | 1994-09-20 | 1996-03-27 | Ono Pharmaceutical Co., Ltd. | Amidinophenol derivatives as protease inhibitors |
Non-Patent Citations (1)
Title |
---|
陈宝泉,等: "甲磺酸萘莫司他的合成", 《中国医药工业杂志》, vol. 38, no. 8, 31 December 2007 (2007-12-31), pages 545 - 546 * |
Also Published As
Publication number | Publication date |
---|---|
CN102225903B (zh) | 2014-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102548560B (zh) | 用于预防和治疗冠心病的组合物和方法 | |
CN113181339B (zh) | 一种醛基类化合物的药物用途 | |
AU2002328494B2 (en) | Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients | |
CN104136436B (zh) | 抗纤维化的化合物及其用途 | |
EP1098651B1 (de) | Neue urokinase-inhibitoren | |
WO1994018185A1 (de) | Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren | |
WO2017053604A1 (en) | Potent antiviral pyrazolopyridine compounds | |
JP2018048178A (ja) | オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類 | |
CN102659630B (zh) | 一种异羟肟酸类化合物及其制备方法和用途 | |
EP3687529B1 (en) | Potent antiviral pyridine-containing compounds | |
WO1996005189A1 (de) | Neue inhibitoren vom benzamidintyp | |
CN105640951B (zh) | 不对称芳香二硫醚类化合物作为病毒3c蛋白酶抑制剂在制备抗病毒药物中的应用 | |
CN102225903B (zh) | 脒基胍基取代芳杂环类化合物的合成方法及其用途 | |
Dixon et al. | Apparent Lack of Interaction Between Dimethyl Sulfoxide (DMSO) and a Variety of Drugs. | |
CN101679358B (zh) | 作为p2y12拮抗剂的吡咯衍生物 | |
CN109912693A (zh) | Rgds修饰的七环醛,其合成,抗栓活性和应用 | |
CN101166534B (zh) | 用于慢性阻塞性肺部疾病的治疗剂 | |
US3809754A (en) | Method of treating diseases of the mucous membrane using compounds of a thiazolidine carboxylic acid and pharmaceutical preparations thereof | |
JPS604186A (ja) | イミダゾキナゾリン化合物 | |
CN106632133B (zh) | 噻唑类衍生物及其制备方法与应用 | |
CN110724102B (zh) | 一种含四氢罂粟碱-3-羧酸甲酯的多酚类化合物及其制备方法和应用 | |
CN102813914B (zh) | 一种用于治疗或预防脑血管及相关疾病的药物组合物 | |
CN109776647A (zh) | 具有抗炎活性的Pyxinol酯化衍生物及其制备方法和应用 | |
US2460139A (en) | Alkamine esters of 2-chloro-4-amino benzoic acid | |
CN109912694A (zh) | Rgdf修饰的七环醛, 其制备,抗栓活性和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: REN JIANDONG Free format text: FORMER OWNER: TIAN FUZHOU Effective date: 20140718 Owner name: TIAN FUZHOU Free format text: FORMER OWNER: REN JIANDONG Effective date: 20140718 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ren Jiandong Inventor after: Tian Fuzhou Inventor after: He Ling Inventor after: Yu Rong Inventor after: Luo Zhulin Inventor after: Wang Ruifeng Inventor before: Tian Fuzhou Inventor before: Ren Jiandong Inventor before: He Ling Inventor before: Yu Rong Inventor before: Luo Zhulin Inventor before: Wang Ruifeng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: TIAN FUZHOU REN JIANDONG HE LING YU RONG ZHULIN LUO WANG RUIFENG TO: REN JIANDONG TIAN FUZHOU HE LING YU RONG ZHULIN LUO WANG RUIFENG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140718 Address after: 610083 Jinniu District, Sichuan Province Rong Avenue, No. 270, No. Applicant after: Ren Jiandong Applicant after: Tian Fuzhou Address before: 610083 Jinniu District, Sichuan Province Rong Avenue, No. 270, No. Applicant before: Tian Fuzhou Applicant before: Ren Jiandong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 Termination date: 20170421 |